NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $33.07 -2.13 (-6.05%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$33.09 +0.02 (+0.06%) As of 09/23/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Pharvaris Stock (NASDAQ:PHVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharvaris alerts:Sign Up Key Stats Today's Range$32.87▼$35.3150-Day Range$32.25▼$38.8652-Week Range$20.65▼$43.25Volume654,170 shsAverage Volume1.04 million shsMarket Capitalization$2.16 billionP/E RatioN/ADividend YieldN/APrice Target$59.87Consensus RatingModerate Buy Company Overview Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group. Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks. The program is designed to provide patients with an oral alternative to currently available injectable or infused therapies. The company has conducted clinical development activities in the United States, Europe and other international markets. Pharvaris’ leadership team includes Chief Executive Officer Berndt Modig, who has experience in the biotechnology and pharmaceutical industries. Deucrictibant remains an investigational product, and Pharvaris’ development programs are subject to the review and approval of regulatory authorities.AI Generated. May Contain Errors. Read More Pharvaris Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePHVS MarketRank™: Pharvaris scored higher than 75% of companies evaluated by MarketBeat, and ranked 175th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPharvaris has a consensus price target of $59.87, representing about 81.0% upside from its current price of $33.07.Amount of Analyst CoveragePharvaris has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharvaris' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pharvaris are expected to grow in the coming year, from ($3.12) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.75% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently increased by 21.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.44 News SentimentPharvaris has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Pharvaris this week, compared to 6 articles on an average week.Search Interest14 people have searched for PHVS on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.MarketBeat Follows12 people have added Pharvaris to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,246,067.00 in company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPharvaris has minimal institutional ownership at this time.Read more about Pharvaris' insider trading history. Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHVS Stock News HeadlinesJohannes Gerardus Chri Schikan Sells 200,000 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 23 at 4:09 AM | americanbankingnews.comElisabeth Bjork Sells 52,500 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 23 at 4:09 AM | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Peng Lu Sells 100,000 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 23 at 4:09 AM | americanbankingnews.comRobert Glassman Sells 14,493 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 22 at 4:22 AM | insidertrades.comRobert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 18, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 6,090 SharesSeptember 17, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $90,265.40 in StockSeptember 16, 2026 | insidertrades.comSee More Headlines PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $27.75 at the beginning of 2026. Since then, PHVS shares have increased by 19.2% and is now trading at $33.07. How were Pharvaris' earnings last quarter? Pharvaris N.V. (NASDAQ:PHVS) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.06. When did Pharvaris IPO? Pharvaris (PHVS) raised $149 million in an initial public offering on Friday, February 5th 2021. The company issued 8,270,500 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. Who are Pharvaris' major shareholders? Pharvaris' top institutional shareholders include venBio Partners LLC (7.10%), Wellington Management Group LLP (3.66%), 5AM Venture Management LLC (1.22%) and Seven Fleet Capital Management LP (1.18%). Insiders that own company stock include Berndt Modig, Johannes Gerardus Chri Schikan, David W Nassif, Anne Lesage, Anne Lesage, Peng Lu, Anna Nijdam, Wim Souverijns, Elisabeth Bjork, Robert Glassman and Viviane Monges. View institutional ownership trends. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharvaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Last Earnings8/12/2026Today9/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PHVS's financial health is in the Green zone, according to TradeSmith. PHVS has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHVS CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees148Year Founded2015Price Target and Rating Average Price Target for Pharvaris$59.87 High Price Target$79.00 Low Price Target$30.00 Potential Upside/Downside+81.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.40% Return on Assets-56.00% Debt Debt-to-Equity RatioN/A Current Ratio11.94 Quick Ratio11.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book7.02Miscellaneous Outstanding Shares65,410,000Free Float57,664,000Market Cap$2.16 billion OptionableNot Optionable Beta-2.33 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PHVS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredMy next big call (under $1)While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...Crypto 101 Media | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
